Portfolio

of candidate-antibiotics in development

DEINOVE builds a portfolio of first-in-class antibiotic candidates, which places it among the major players in the field, by bringing together a European network of expertise (Morphochem, bioMérieux, Naicons),

DEINOVE is preparing the entry into Phase II of a first antibiotic candidate targeting severe gastrointestinal infections caused by Clostridium difficile. This candidate is also evaluated by the USAMRIID (United States Army Medical Research Institute of Infectious Diseases) against Bacillus anthracis that triggers anthrax and Francisella tularensis that triggers tularemia or rabbit fever, both bacteria being classified in the “high priority” category of biothreat agents.

Anti-Gram Positive first-in-class
Proprietary program

Gastrointestinal Clostridium difficile infections

intravenous
Preclinical
Phase I
Phase II
Phase III

Bacillus anthracis and Francisella tularensis

Evaluated by the USAMRIID
Preclinical
Phase I
Phase II
Phase III
Anti-Gram positive
Proprietary program

New antibiotic structure

Preclinical
Phase I
Phase II
Phase III